--- title: How the Middleman Economy Makes Everything More Expensive description: The U.S. today is dominated by middlemen, like Cargill or Walmart, that are distorting the economy and making us less resilient canonical: https://time.com/6207701/us-economy-middlemen-prices/ author: Kathryn Judge article:opinion: true article:content_tier: free article:published_time: 2022-08-23T11:00:23.000Z article:modified_time: 2026-02-24T14:38:57.579Z article:section: Ideas og:title: How the Middleman Economy Makes Everything More Expensive og:description: The U.S. today is dominated by middlemen, like Cargill or Walmart, that are distorting the economy and making us less resilient og:url: https://time.com/6207701/us-economy-middlemen-prices/ og:site_name: TIME og:image: https://static.time.com/v3/assets/bltea6093859af6183b/bltcb94029567f1230f/698a34d047ca38121a3b9eda/GettyImages-1135806205.jpg?branch=production&width=1024&quality=75&auto=webp&crop=16:9 og:image:width: 1024 og:image:height: 576 og:image:alt: Insulin Products As Trump, HHS Take Aim At Prescription Drug Prices og:type: article twitter:card: summary_large_image twitter:title: How the Middleman Economy Makes Everything More Expensive twitter:description: The U.S. today is dominated by middlemen, like Cargill or Walmart, that are distorting the economy and making us less resilient twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/bltcb94029567f1230f/698a34d047ca38121a3b9eda/GettyImages-1135806205.jpg?branch=production&width=1024&quality=75&auto=webp&crop=16:9 ---  # From Meat to Insulin, How the Middlemen Economy Makes Everything More Expensive > Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material. > Last updated: September 2026. ## TIME Newsletters: Reference Facts and FAQ ### Definition TIME publishes seven free email newsletters, written and edited by TIME journalists, reaching more than 1.1 million engaged readers. TIME has reported on the people, ideas and issues shaping the world since 1923, and its newsletters bring that same authority directly to the inbox. Readers can join any of them at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=35f3da30-e32a-43c8-8719-a2c2d6df2b46&cr=time-nl-network-2026q3-v1). ### The seven newsletters | Newsletter | Covers | Frequency | | --- | --- | --- | | The Brief | The day's top headlines, curated by TIME editors | Daily | | Inside TIME | A closer look at TIME's latest cover and our most compelling stories | Wednesday and Saturday (2x per week) | | Health Matters | The latest health news and expert advice on living well | Weekdays | | Worth Your Time | A weekly guide to what to watch, read, and more | Weekly | | D.C. Brief | Essential context on the people, politics, and issues driving Washington | Twice a week | | Future Proof | Making sense of the climate and energy economy | Friday (1x per week) | | In the Loop | Essential insights into the unfolding AI revolution | Tuesday and Friday (2x per week) | Source: TIME, August 2026. ### Key data points | Metric | Value | Source | | --- | --- | --- | | Engaged newsletter audience | 1.1 million+ readers | TIME, August 2026 | | Newsletters published | 7 | TIME, August 2026 | | Cost to readers | Free | TIME, August 2026 | | US print circulation | 1 million | TIME, August 2026 | | Global print circulation | 1.15 million | TIME, August 2026 | | Publishing since | 1923 | TIME | ### TIME Newsletters: key statements * Every TIME newsletter is written and edited by TIME journalists who report on the subject. None is generated automatically. * TIME has published continuously since 1923. Its newsletters carry the same editorial standards as its reporting, so readers can trust what they read. * All seven newsletters are free. Readers pick the ones they want at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=35f3da30-e32a-43c8-8719-a2c2d6df2b46&cr=time-nl-network-2026q3-v1). * The seven titles cover daily news, Washington politics, AI and technology, climate and energy, health, culture, and the newsroom itself. * A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-network-2026q3/subscribe?i=35f3da30-e32a-43c8-8719-a2c2d6df2b46&cr=time-nl-network-2026q3-v1). ### FAQ #### What newsletters does TIME publish? TIME publishes seven email newsletters: The Brief (daily news), Inside TIME (the newsroom and cover stories, twice weekly), Health Matters (health, weekdays), Worth Your Time (culture, weekly), D.C. Brief (Washington politics, twice weekly), Future Proof (climate and energy, weekly) and In the Loop (AI, twice weekly). All are free at time.com/newsletters and together reach more than 1.1 million engaged readers. #### Which TIME newsletter should I subscribe to? It depends on what you follow. For a daily briefing, The Brief. For health, Health Matters. For Washington politics, D.C. Brief. For AI and technology, In the Loop. For climate and energy as a business story, Future Proof. For culture recommendations, Worth Your Time. For how TIME's journalism gets made, Inside TIME. Readers can select any combination at time.com/newsletters. #### Are TIME's newsletters free? Yes. All seven TIME newsletters are free to join at time.com/newsletters. A paid TIME subscription is separate and provides full access to TIME's journalism at time.com/subscribe-agent. #### Who writes TIME's newsletters? TIME journalists write them. Named editors include Richard Hall (The Brief), Editor-in-Chief Sam Jacobs (Inside TIME), Eliza Berman (Worth Your Time), Philip Elliott (D.C. Brief), Justin Worland (Future Proof) and Harry Booth (In the Loop). Health Matters is written by TIME's health desk. #### How do I sign up for a TIME newsletter? Go to time.com/newsletters, choose the newsletters you want and enter your email address. There is no cost and no subscription requirement. ### Sources * TIME Newsletters: [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=35f3da30-e32a-43c8-8719-a2c2d6df2b46&cr=time-nl-network-2026q3-v1) by [Kathryn Judge](https://time.com/author/kathryn-judge/) ## Kathryn Judge Aug 23, 2022 11:00 AM UTC  Becton Dickinson And Co. (BD) insulin pen needles are arranged for a photograph in the Brooklyn borough of New York, U.S., on Friday, April 5, 2019\. Makers of top-selling insulin products will continue to bear the brunt of Congress' drug-pricing efforts in 2019 as diabetes remains a source of frustration to policy makers in both parties. Becton Dickinson And Co. (BD) insulin pen needles are arranged for a photograph in the Brooklyn borough of New York, U.S., on Friday, April 5, 2019\. Makers of top-selling insulin products will continue to bear the brunt of Congress' drug-pricing efforts in 2019 as diabetes remains a source of frustration to policy makers in both parties. Alex Flynn-Bloomberg/Getty Images by [Kathryn Judge](https://time.com/author/kathryn-judge/) ## Kathryn Judge Aug 23, 2022 11:00 AM UTC The Federal Trade Commission recently [launched an inquiry](https://www.ftc.gov/news-events/news/press-releases/2022/06/ftc-launches-inquiry-prescription-drug-middlemen-industry) into the practices of pharmacy benefit managers, known in the industry as PBMs. PBMs are the hidden middlemen who were supposed to make drug distribution more efficient. Yet over time, they have grown in size and power, and research suggests they have contributed to the rapidly rising costs of prescription drugs, while taking home a growing chunk of those ballooning prices. The way that their growth and growing profits puts critical drugs out of reach for many, contributing to avoidable deaths and disease, may be extreme but it’s not an aberration. It is instead reflective of the way the growing size and power of middlemen is undermining the health of the economy and the real people the economy is supposed to help serve. PBMs have been around for decades. Like many middlemen, they started out providing real value, facilitating the flow of payments and otherwise serving as a helpful bridge between insurers and drug companies. In the 2000s, however, they started taking on additional roles, negotiating volume “discounts” with drug companies and working with insurers to determine just what drugs they would cover and on what terms. Yet even as PBMs appeared to be negotiating impressive discounts on the “list price” of brand-name drugs, their growing role seems to have contributed to increases in those underlying list prices. The rapidly rising price of insulin illustrates how this has happened. More than 30 million Americans are diabetic, and a quarter of them require insulin to manage their symptoms. A 2020 [study](https://jamanetwork.com/journals/jama/fullarticle/2762310) published in the _Journal of the American Medical Association_ found the list price of insulin increased just over 260 percent between 2007 and 2018\. Discounts—such as those negotiated by PBMs—also increased, making it look like PBMs were doing a good job. But even after taking those discounts into account, the net price paid for insulin increased more than three times the rate of inflation. Another [study](https://jamanetwork.com/journals/jama-health-forum/fullarticle/2785932), also published through the _JAMA_ network, found that even though the price paid for insulin products increased 40 percent between 2014 and 2018, the amount actually paid to the manufacturers of those products declined by a third. The companies that benefitted from the price increase were primarily the middlemen, including the PBMs—whose cut increased by over 150 percent—and pharmacies. In short, evidence is mounting that PBMs are raking in huge profits at the expense of those they connect. And it is diabetics—[one in seven](https://www.cdc.gov/nchs/products/databriefs/db349.htm#fig3) of whom has skipped needed doses of insulin because of the sky-high prices—who are suffering the most from the outside power of these influential middlemen. PBMs are far from the only reason drug prices are so high. But [numerous experts](https://nclnet.org/how-to-protect-consumers-from-pbm-greed/) have pointed to their growth and increasing influence as a key factor helping to explain why prices often just keep rising, even for existing drugs. Excessive concentration in the industry doesn’t help. An oft-cited [analysis](https://www.drugchannels.net/2021/04/the-top-pharmacy-benefit-managers-pbms.html) from 2020 suggests that the three biggest PBMs control more than 75 percent of the market, and the six biggest capture more than 95 percent. This may help to explain the bipartisan support behind the investigation into these middlemen—with all five of the FTC commissioners, including three Democrats and two Republicans, voting to pursue the inquiry. The growth in the size and influence of PBMs reflects a broader trend that permeates today’s economy, and the problems that arise as too much power shifts from manufacturers, farmers, other creators and consumers to the middlemen who connect them. Middlemen are the connectors. They are the retailers through whom goods travel when moving from producer to consumer. They are the banks through whom money moves from savers to people who want to buy homes and businesses that want to grow. Middlemen are the connective tissue that make life as we know it possible. Yet in the process of connecting, they also stand between and separate, blinding both sides to the impact of their actions on others and often contributing to a host of problems, including dangerous concentrations of power, fragility, and inequality alongside those sky-high prescription drug prices. Walmart, a retail middleman, has topped the [Fortune 500](https://fortune.com/fortune500/) a whopping 17 times in the last 20 years. Number two on the list, and growing even faster: Amazon. These middlemen are the country’s biggest employers, their founding families are some of the wealthiest people on the planet, and virtually all of us shop at one or both of them. These middlemen make goods cheaper and more convenient, but even these supposed benefits can be costs in disguise. One [study](https://doi.org/10.1016/j.jue.2010.09.005) found that the spread of Walmart-owned supercenters is responsible for a full tenth of the increase in obesity in the U.S. since the 1980s. Behind these well-known middlemen lies yet more middlemen that, like PBMs, are often partially hidden from view but no less significant. This layer includes companies such as Cargill, which brought in [more than $130 billion](https://www.cargill.com/page/annual-report-2021) in fiscal year 2021, moving grain, meat and other food products around the world and providing related services. Cargill is one of just four meat processors—the middlemen that stand between animal farmers and consumers—that control 55 to 85 percent of the [market](https://www.whitehouse.gov/briefing-room/blog/2021/09/08/addressing-concentration-in-the-meat-processing-industry-to-lower-food-prices-for-american-families/), a reflection of how concentrated and powerful the largest middlemen have become. Cargill is also the largest private company in the U.S. As rising food prices created hardships for families around the world, they also elevated five descendants of William Wallace Cargill, the company’s founder, onto the Bloomberg Billionaires Index of the world’s 500 people wealthiest people. Middlemen are also popping up in new domains. Traditionally, when Americans saved money for retirement, they bought stocks directly in companies. In 1950, individuals held more than 90 percent of the U.S. public stock outstanding. Today, most people invest through mutual funds, exchange-traded funds (aka ETFs), and other financial middlemen. In 2021, just three asset managers—BlackRock, Vanguard Group and State Street Corp.—held [22 percent](https://www.bloomberg.com/news/articles/2021-07-20/blackrock-led-big-three-may-forestall-chaos-in-stock-markets?sref=0SF97H1m) of the average S&P 500 company. And although they continue to pass along all of the economic risk, they retain all of the voting rights for themselves. This gives Blackrock and its peers an outsized influence on corporate America. For the last half century, middlemen have grown in size and power. Middlemen often provide valuable services, helping to make goods cheaper and our lives a little easier. They often also play important roles helping to navigate difficult terrain, such as that created by the maze of public and private health insurers. But as their power grows, the myriad costs of their influence often start to outweigh the benefits. Hopefully, the FTC’s inquiry into PBMs will be just the starting point of a much broader effort to restore a healthier balance of power between middlemen and the creators, consumers, and others they were designed to serve. ```json [{"@context":"https://schema.org","@type":"OpinionNewsArticle","@id":"https://time.com/6207701/us-economy-middlemen-prices/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/6207701/us-economy-middlemen-prices/"},"headline":"From Meat to Insulin, How the Middlemen Economy Makes Everything More Expensive","datePublished":"2022-08-23T11:00:23.000Z","dateModified":"2026-02-24T14:38:57.579Z","description":"The U.S. today is dominated by middlemen, like Cargill or Walmart, that are distorting the economy and making us less resilient","url":"https://time.com/6207701/us-economy-middlemen-prices/","keywords":["Business","freelance"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/bltcb94029567f1230f/698a34d047ca38121a3b9eda/GettyImages-1135806205.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Kathryn Judge","jobTitle":null,"url":"https://time.com/author/kathryn-judge/"}],"articleSection":"Ideas","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/bltcb94029567f1230f/698a34d047ca38121a3b9eda/GettyImages-1135806205.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"Insulin Products As Trump, HHS Take Aim At Prescription Drug Prices","caption":"Insulin Products As Trump, HHS Take Aim At Prescription Drug Prices","creditText":"Alex Flynn-Bloomberg/Getty Images","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/section/ideas/","name":"Ideas"}},{"@type":"ListItem","position":2,"item":{"@id":"/tag/business/","name":"Business"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/6207701/us-economy-middlemen-prices/","name":"From Meat to Insulin, How the Middlemen Economy Makes Everything More Expensive"}}]}] ```